World News: 10:38 GMT Tuesday 14th January 2020. [Research and Markets via Globe Newswire via SPi World News]
Dublin, Jan. 14, 2020 (GLOBE NEWSWIRE) -- The report has been added to offering.
The global neoantigen cancer vaccine industry analysis projects the market to grow at a significant CAGR of 34.69% during the forecast period, 2023-2030.
The neoantigen cancer vaccine market is expected to generate $227.1 million revenue in 2023, owing to the expected launch of first neoantigen vaccine Tedopi in the market. Further, the market is forecast to generate $1,826.1 million revenue by 2030.
The neoantigen cancer vaccine market report provides a holistic view of the market in terms of various factors influencing it, including reported clinical findings, financing and partnership opportunities, expected market and current clinical landscape.The scope of this report is centered upon conducting a detailed study of the products expected to be allied with the oncology market. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of key players, growth potential of each underlying sub-segment, and company, as well as other vital information with respect to the global neoantigen cancer vaccine market.
For more information about this report visit
Research and Markets also offers services providing focused, comprehensive and tailored research.
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Globe Newswire: 10:38 GMT Tuesday 14th January 2020
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2020. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.